Navigation Links
Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Enhance Efficiency and Scale-up of its Malaria Vaccine Manufacturing Process
Date:9/15/2009

ROCKVILLE, Md., Sept. 16 /PRNewswire-USNewswire/ -- Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The award for two years is $1.99 million. Subject to satisfactory progress by Sanaria, continued funding for a third year will bring the total to nearly $3 million. This new funding will facilitate efforts to increase the efficiency and scale-up of manufacturing and release processes to the levels required for Phase 3 clinical testing, licensure, and commercial launch of Sanaria(TM) PfSPZ, Sanaria's attenuated whole parasite malaria sporozoite vaccine.

Sanaria(TM) PfSPZ Vaccine entered Phase 1 clinical trials of safety and efficacy at the Naval Medical Research Center and the University of Maryland School of Medicine's Center for Vaccine Development in the spring of 2009. Since 2003, peer-reviewed NIAID SBIR grants have provided Sanaria with over $17 million in financial support.

About Sanaria(TM) PfSPZ Vaccine

Sanaria(TM)( )PfSPZ Vaccine consists of live sporozoite-stage Plasmodium falciparum parasites weakened (attenuated) by exposure to radiation. Such sporozoites, delivered to human volunteers by the bite of infected mosquitoes, have been shown to confer protection against malaria. Sanaria has developed novel technologies and facilities to successfully translate research findings from a handful of volunteers receiving mosquito-administered sporozoites to a bona fide vaccine that can be clinically tested and conventionally administered to hundreds of millions of recipients. Although live, attenuated pathogens are commonly used to vaccinate against many viral and bacterial diseases, the Sanaria(TM)( )PfSPZ Vaccine is unique among vaccines designed to prevent malaria. For the first time, an immunogen conferring high levels of protection against malaria has been formulated as a stable, injectable vaccine candidate that meets regulatory standards.

About Sanaria Inc.

Sanaria Inc. was founded in 2003. The company's primary mission is to develop and commercialize attenuated whole-parasite malaria vaccines that confer high-level, long-lasting protection against Plasmodium falciparum, the parasite responsible for most of the malaria-associated severe illness and death worldwide. Sanaria's corporate headquarters, administrative, research, development, and manufacturing operations are located in Rockville, Maryland. The company's Web site is http://www.sanaria.com.

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. Such statements include the assessment of the vaccine candidate, the expectations for immunity of the vaccine, and belief concerning the measure of success. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the Company's ability to raise sufficient funds, the regulatory approval process, dependence on third-parties, clinical trials results, and the ability to commercialize the vaccine.

For further information contact:

Media- Adam Richman 301.770.3222, Investors- Robert Thompson 240.403.2750


'/>"/>
SOURCE Sanaria Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Malaria Vaccine Developer Sanaria Inc. and the University of Maryland Biotechnology Institute Awarded Collaborative, Multi-Year, US $600,000 NIH Phase I Small Business Innovation Research Grant
2. KV Pharmaceutical Receives Stockholder Action by Written Consent
3. gloStreams gloEMR Version 5.0 Receives 08 CCHIT Certification
4. Center for AIDS Intervention Research Medical receives $11.16 million NIH grant
5. Rib-X Pharmaceuticals Receives Award from NIAID to Develop Antibiotic Treatment for Gonorrhea
6. Digestive Care, Inc. Receives Complete Response Letter from FDA for PANCRECARB(R) (pancrelipase)
7. COLD-FX(R) Receives Highest Sports Certification in North America
8. Project Lifesaver International Receives Federal Assistance for the Missing Alzheimers Patient Assistance Program
9. RZN Nutraceuticals Receives United States Patent & Trademark Office Notice of Allowance for Proprietary HerbaZorb(TM) Absorption and Delivery System Technology Used in Popular Arthri-Zen Relief(R) and Migra-Zen Relief PLUS(R) Products
10. UM receives grant to support graduate students in the family nurse practitioner program
11. Par Pharmaceutical Receives Final Approval To Market Generic Starlix(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology: